Abstract
Lazertinib is an oral, potent, highly mutant-selective, and brain-penetrant third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both EGFR activating mutations and EGFR T790M while sparing wild-type EGFR. We report the efficacy and safety of lazertinib 240 mg as a frontline treatment in EGFR mutated, advanced or metastatic non-small cell lung cancer (NSCLC) in Part C frontline cohort of a single-arm phase I/II study (ClinicalTrials.gov identifier: NCT03046992).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
